A stabilised GHRH analog (Egrifta), FDA-approved to reduce excess visceral fat in HIV-associated lipodystrophy.
A degradation-resistant growth-hormone-releasing hormone analog that binds pituitary GHRH receptors to stimulate natural pulsatile GH release, raising IGF-1 and promoting lipolysis in visceral fat — preserving the body's own GH feedback rather than supplying exogenous GH.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
No reviews yet. If you've used Tesamorelin, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.